Print

HIV-V-A004

Safety, Tolerability, and Immunogenicity Study of Homologous Ad26 Mosaic Vector Vaccine Regimens or Heterologous Ad26 Mosaic and MVA Mosaic Vector Vaccine Regimens With Glycoprotein 140 (gp140) for Human Immunodeficiency Virus (HIV) Prevention

Trial Details:

I/II Ongoing
Crucell Holland BV; NIAID; US Military HIV Research Program; Beth Israel Deaconess Medical Center; IAVI December 16, 2014
Ad26.Mos.HIV Trivalent,gp140 C,MVA mosaic MVA Ad 26 mosaic; Protein gp140 C
Ad26.Mos.HIV Trivalent Viral Vector - Adeno
gp140 C Protein
MVA mosaic Viral Vector - Pox
USA, Rwanda, South Africa, Thailand, Uganda 400
NCT02315703
https://clinicaltrials.gov/ct2/show/NCT02315703